Jazz Pharmaceuticals (JAZZ) Cash from Financing Activities (2010 - 2026)

Jazz Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$78.5 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 90.35% year-over-year to -$78.5 million; the TTM figure through Mar 2026 stood at -$138.4 million (up 81.21% YoY), while the FY2025 annual figure was -$873.4 million, down 4357.07% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$78.5 million, down from $75.4 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $246.4 million in Q3 2024, with the low at -$813.5 million in Q1 2025.
• The 5-year median for Cash from Financing Activities is -$78.5 million (2023), against an average of -$103.9 million.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 1581.78% in 2022, then jumped 1011.66% in 2025.
• Jazz Pharmaceuticals' Cash from Financing Activities stood at $19.6 million in 2022, then sank by 611.87% to -$100.3 million in 2023, then surged by 91.75% to -$8.3 million in 2024, then surged by 1011.66% to $75.4 million in 2025, then tumbled by 204.06% to -$78.5 million in 2026.
• Business Quant data shows JAZZ's Cash from Financing Activities at -$78.5 million in Q1 2026, $75.4 million in Q4 2025, and -$10.8 million in Q3 2025.